Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.
Watanabe T et al. PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662.

High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma.
Chhabra S et al. J Hematol Oncol. 2015 Jun 25;8(1):77.

Changes in circulating endothelial progenitor cells predict responses of multiple myeloma patients to treatment with bortezomib and dexamethasone.
Wang L et al. Braz J Med Biol Res. 2015 Jun 23:1-7. [Epub ahead of print].

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J et al. Cytometry B Clin Cytom. 2015 Jun 23. doi: 10.1002/cyto.b.21265. [Epub ahead of print].

Extramedullary Soft Tissue Involvement and Discrepant Osseous Uptake on Tc-99m MDP and Ga-67 Citrate Scintigraphy in a Patient With Multiple Myeloma: A Case Report and Literature Review.
Tsai SY et al. Medicine (Baltimore). 2015 Jun;94(24):e995. doi: 10.1097/MD.0000000000000995.

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.
Martínez-López J et al. Blood. 2015 Jun 18. pii: blood-2015-04-638742. [Epub ahead of print].

Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring ofmultiple myeloma patients.
Batinić J et al. Croat Med J. 2015 Jun 19;56(3):263-71.

Using a latent class model to refine risk stratification in multiple myeloma.
Qu P et al. Stat Med. 2015 Jun 17. doi: 10.1002/sim.6557. [Epub ahead of print].

Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration: an Italian national cancer institute experience.
Marchesi F et al. Br J Haematol. 2015 Jun 17. doi: 10.1111/bjh.13549. [Epub ahead of print].

PET/CT improves the definition of complete response  and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma.
Zamagni E et al. Clin Cancer Res. 2015 Jun 15. pii: clincanres.0396.2015. [Epub ahead of print].

Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma.
Chen J et al. PLoS One. 2015 Jun 15;10(6):e0127022. doi: 10.1371/journal.pone.0127022. eCollection 2015.

Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT.
Ak İ et al. Ann Hematol. 2015 Jun 13. [Epub ahead of print].

CD20+ multiple myeloma: can we use conventional chemotherapy to achieve ideal outcome for these patients?
Huang B et al. Leuk Lymphoma. 2015 Jun 12:1-23. [Epub ahead of print].

Prevention of thromboembolism in Myeloma: expanding the tool-box of assays to predict the risk?
Burbury KL et al. Leuk Lymphoma. 2015 Jun 8:1-9. [Epub ahead of print].

Prognostic Significance of Initial Serum Albumin and 24 Hour Daily Protein Excretion before Treatment inMultiple Myeloma.
Chen JH et al. PLoS One. 2015 Jun 8;10(6):e0128905. doi: 10.1371/journal.pone.0128905. eCollection 2015.